Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
University of Liverpool · Royal Liverpool University Hospital · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,920
total citations
- FWCI
- 93.96
- Percentile
- 100%
- References
- 33
Citations per year
Authors
34- JPJohn P. NeoptolemosCorresponding
University of Liverpool, Royal Liverpool University Hospital
- DHDaniel H. Palmer
University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust
- PGPaula Ghaneh
University of Liverpool, Royal Liverpool University Hospital
- EEEftychia Eirini Psarelli
University of Liverpool
- JWJuan W. Valle
University of Manchester, The Christie NHS Foundation Trust
Topics & keywords
Topics
Keywords
- Gemcitabine
- Capecitabine
- Medicine
- Open label
- Pancreatic cancer
- Oncology
- Deoxycytidine
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.